<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Transplantation-associated <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e> (TA-<z:chebi fb="39" ids="18139,53050">TMA</z:chebi>) has been associated with significantly reduced survival following allogeneic bone marrow transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>In this study we describe the course and response to plasma exchange therapy of TA-<z:chebi fb="39" ids="18139,53050">TMA</z:chebi> as well as risk factors for its' development </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-five patients who underwent plasma exchange therapy were matched to fifty control patients selected for transplant indication and stage of disease at the time of transplant </plain></SENT>
<SENT sid="3" pm="."><plain>Transplant indications were <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Groups were well balanced with respect to disease status, age at time of transplant and use of radiation-based conditioning </plain></SENT>
<SENT sid="5" pm="."><plain>TA-<z:chebi fb="39" ids="18139,53050">TMA</z:chebi> was diagnosed a median of 27 days after transplantation and <z:hpo ids='HP_0000707'>neurological abnormalities</z:hpo> were present in ten cases </plain></SENT>
<SENT sid="6" pm="."><plain>Patients received a median of 10 (range 2-43) plasma exchange treatments </plain></SENT>
<SENT sid="7" pm="."><plain>Hematological responses were recorded in eight cases </plain></SENT>
<SENT sid="8" pm="."><plain>Risk factors for the development of TA-<z:chebi fb="39" ids="18139,53050">TMA</z:chebi> included transplantation from unrelated donors (p = 0.002), <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">hepatic venoocclusive disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>) (p = 0.034), grade 2-4 <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) (p = 0.042) and <z:e sem="disease" ids="C0004610" disease_type="Disease or Syndrome" abbrv="">bacteremia</z:e> with diphtheroid organisms (p = 0.009) </plain></SENT>
<SENT sid="9" pm="."><plain>Only hepatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> (p = 0.0026) and grade 2-4 <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (p = 0.0436) remained significant risk factors for later development of TA-<z:chebi fb="39" ids="18139,53050">TMA</z:chebi> in a multivariate logistic regression model </plain></SENT>
<SENT sid="10" pm="."><plain>The median survival of patients with TA-<z:chebi fb="39" ids="18139,53050">TMA</z:chebi> was 66 (range 32-733) days while that of unaffected patients was 742 (range 15-2392) days after transplantation </plain></SENT>
<SENT sid="11" pm="."><plain>Only one patient with TA-<z:chebi fb="39" ids="18139,53050">TMA</z:chebi> remains alive 733 days after transplantation </plain></SENT>
</text></document>